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Abstract
Background: Noninvasive prenatal testing (NIPT) to detect fetal aneuploidy using next-generation sequencing on
ion semiconductor platforms has become common. There are several sequencers that can generate sufficient DNA
reads for NIPT. However, the approval criteria vary among platforms and countries. This can delay the introduction
of such devices and systems to clinics. A comparison of the sensitivity and specificity of two different platforms
using the same sequencing chemistry could be useful in NIPT for fetal chromosomal aneuploidies. This would
improve healthcare authorities’ confidence in decision-making on sequencing-based tests.
Methods: One hundred and one pregnant women who were predicted at high risk of fetal defects using
conventional prenatal screening tests, and who underwent definitive diagnosis by full karyotyping, were enrolled
from three hospitals in Korea. Most of the pregnant women (69.79 %) received NIPT during weeks 11–13 of
gestation and 30.21 % during weeks 14–18. We used Ion Torrent PGM and Proton semi-conductor-based
sequencers with 0.3× sequencing coverage depth. The average total reads of 101 samples were approximately
4.5 and 7.6 M for PGM and Proton, respectively. A Burrows-Wheeler Aligner (BWA) algorithm was used for the
alignment, and a z-score was used to decide fetal trisomy 21. Interactive dot diagrams from the sequencing data
showed minimal z-score values of 2.07 and 2.10 to discriminate negative versus positive cases of fetal trisomy 21 for
the two different sequencing systems.
Results: Our z-score-based discrimination method resulted in 100 % positive and negative prediction values for
both ion semiconductor PGM and Proton sequencers, regardless of their sequencing chip and chemistry
differences. Both platforms performed well at an early stage (11–13 weeks of gestation) compared with previous
studies.
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Conclusions: These results suggested that, using two different sequencers, NIPT to detect fetal trisomy 21 in early
pregnancy is accurate and platform-independent. The data suggested that the amount of sequencing and the
application of common, simple, and robust statistical analyses are more important than sequencing chemistry and
platform types. This result has practical implications in countries where PGM is approved for NIPT but the Proton
system is not.
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Background
Recently, early stage prenatal screening to detect fetal
aneuploidy has become common for pregnant women
[1, 2]. Women over the age of 35 have an increased risk
of giving birth to an abnormal baby; hence, accurate
prediction-based tests for fetuses are required. Several
prenatal screening methods are in use. Common first-
trimester screening comprises a combination of ultra-
sound and maternal serum markers [3]. Women at high
risk for fetal chromosome abnormalities have the option
to undergo invasive prenatal diagnostic tests such as
chorionic villus sampling (CVS) at 10–13 weeks gesta-
tional age or amniocentesis at 15–18 weeks gestational
age [4, 5]. However, these tests are reported to be associ-
ated with iatrogenic pregnancy loss [6].
Decades ago, researchers discovered that cancer DNA
could be detected as both circulating tumor cells and
cell-free DNA (cfDNA) in human blood. Using this
observation, researchers proposed that fetal DNA could
be detected using molecular assays and cell-free fetal
DNA (cffDNA) was indeed detected in maternal blood
[7]. Today, women can choose noninvasive prenatal test-
ing (NIPT) of cffDNA [8]. CffDNA is generally produced
from apoptotic trophoblasts in the placenta [7] during
pregnancy, and the amount of cffDNA increases with
gestational age. During weeks 10–22 of gestation, ap-
proximately 10 % of free DNA in the mother’s plasma is
estimated to be cffDNA. There is a very high level of
variance in the fraction and amount of cffDNA among
individuals [9]. Therefore, applying molecular testing re-
quires an extremely accurate detection approach or a
massive amount of data to overcome this detection diffi-
culty. Our previous work [10] showed that it is possible
to detect fetal chromosome abnormalities for pregnant
women in weeks 12–21 of gestation by amplifying and
producing a large number of DNA fragments for quanti-
tative analyses. The percentage of cffDNA is propor-
tional to gestational age; therefore, it is important to
perform the test at the right time. At the early stage of
pregnancy, the fraction of fetal DNA is perhaps the most
important factor for NIPT, because the common aneu-
ploidies are very difficult to detect for pregnant women
in the early weeks of gestation [11] because of the lack
of fetal DNA.
To carry out efficient NIPT, it is necessary to under-
stand the limitations and characteristics of cffDNA. For
example, cffDNA is normally only around 150 base pairs
(bp) [12]. Also, cffDNA has a short half-life of about
16 min [13, 14].
NIPT technologies have been well accepted because of
two critical clinical benefits: there is no risk of preg-
nancy loss and NIPT can be used as an early pregnancy
test compared with amniocentesis; however, discordant
NIPT data resulting from placental or maternal cell mo-
saicism requires full karyotyping, which is the gold
standard for aneuploidy tests, to confirm positive out-
puts [15–17].
Nowadays, next-generation sequencing (NGS) is
widely used for NIPT [18–24]. Ion Torrent PGM from
Life Technologies, a semiconductor-based sequencing
platform assessed here for NIPT and compared with its
later and larger-capacity version of Ion Torrent Proton,
enables a reduced turnaround time of sequencing data
to within 2 to 4 h for a clinical sequencing service. A
recent study described the outcomes for noninvasive
detection of common fetal trisomy 13, 18, and 21 using
the ion semiconductor platform, Ion Proton, which pro-
duced greater than 98 % sensitivity and specificity [23].
However, there are many different types and versions of
sequencers, making it necessary for granting authorities
to evaluate the generality and robustness of such se-
quencers for NIPT.
As far as we know, there has been no direct compari-
son between PGM and Proton sequencers for NIPT with
large sample sizes. Another reason to compare PGM
and Proton sequencers is that PGM is faster. The turn-
around time for clinical applications is very important,
and ion semiconductor sequencers, such as PGM, have
been widely accepted because of their simplicity and
speed. Prenatal testing using PGM has become feasible
for the noninvasive detection of fetal aneuploidy [25].
PGM machines are small and inexpensive; therefore,
comparing the benefits and overall accuracy of both
PGM and Proton in terms of data produced could be
important clinically for doctors who would like to use
NIPT. The experimental cost of the bench-top PGM se-
quencer is much lower than other common sequencers,
although PGM’s general sequencing accuracy is lower.
Kim et al. BMC Medical Genomics  (2016) 9:22 Page 2 of 7
From Ion 314/316/318 chips of PGM, 70 Mbp to 2 Gbp
of raw sequencing data can be produced, and 85 % of
the reads usually reaches Q20, a common sequencing
quality threshold. With the Ion Proton platform, nearly
10 Gbp of raw sequencing data are produced with ap-
proximately 75 % of them reaching Q20. This amount is
sufficient to determine the quantitative variation caused
by chromosomal abnormality. A recent study confirmed
that high-throughput ion semiconductor sequencing was
feasible in noninvasive prenatal testing of fetal aneu-
ploidies [10, 23]. In that study, only eight maternal
plasma DNA samples were used, comprising four nor-
mal pregnancies and four with trisomy 21 fetuses, which
were sequenced on Ion Torrent 314/316/318/PI chips
[26]. Separately, using different samples, Ion Proton
sequencer-based results have also demonstrated success-
fully that ion semiconductor sequencing is suitable for
NIPT [10, 23].
Here, we compared the Ion Torrent PGM and Proton
platforms for NIPT for fetal trisomy 21 directly using
PGM and Proton simultaneously for the same set of
samples to provide some general applicability of ion
semiconductor-based sequencers. We were also inter-
ested in demonstrating whether any sequencers could
discriminate fetal aneuploidy from normal chromosomes
in blood, even if the fetal DNA fraction is not sufficient
for NIPT. In doing so, we tried to detect fetal trisomy 21
for the pregnant women, most of whom (69.79 %) were
at weeks 11 to 13 of gestation.
Methods
Study subjects
From December 2014 to April 2015, 101 pregnant
women aged between 25 and 42 years (Table 1) were
enrolled under an Institutional Review Board protocol in
three hospitals (Mirae & Heemang, Namujungwon, and
GN in Korea) after high-risk group screening. Sixty-seven
of them (69.79 %) were at weeks 11–13 of gestation, and
29 (30.21 %) were at weeks 14–18 of gestation. Partici-
pants underwent invasive diagnostic testing (amniocen-
tesis) for fetal karyotyping, the results of which were
blinded. Before amniocentesis, they agreed to participate
in this study, donated their blood samples, and provided
written informed consent.
We used the outcomes of the standard prenatal aneu-
ploidy screening with individual risk scores and interpre-
tations generated by accredited clinical laboratories to
identify the group at high risk of fetal defects. First-
trimester serum markers included pregnancy-associated
plasma protein A (PAPP-A) and free beta subunit or
total human chorionic gonadotropin (hCG). A low level
of PAPP-A and high hCG might indicate Down syn-
drome. First-trimester serum markers were used in com-
bination with sonographic measurement of fetal nuchal
translucency to classify the women into high- or low-
risk groups. The second-trimester serum test, termed
quadruple screening, was used alone to evaluate and
define aneuploidy risk. Chromosomal abnormality was
tested with cultured fetal cells from amniotic fluid, as
described by Barch et al. [27]. The result of cytogenetic
analysis on all 101 pregnant women indicated that 96
(95.0 %) were chromosomally normal, and five (5.0 %)
had trisomy 21.
CfDNA preparation and massively parallel short read
sequencing
More than 10 mL of peripheral blood was collected and
stored in a BCT™ tube (Streck, Omaha, NE, USA). The
blood sample was centrifuged at 1200 × g for 15 min at
4 °C. The plasma portion was transferred to micro-
centrifuge tubes and centrifuged again at 16,000 × g for
10 min at 4 °C. One mL of plasma was used to extract
cfDNA, using a QIAamp Circulating Nucleic Acid Kit
(Qiagen, Netherland). The end-repair of the plasma
cfDNA was performed using T4 DNA polymerase,
Klenow DNA polymerase and T4 polymerase kinase.
DNA libraries for the Ion PGM and Proton sequencing
systems were prepared according to the protocol provided
by the manufacturer (Life Technologies, SD, USA). PGM
318 and Proton PI Chip Kit version 2.0 were used to pro-
duce an average of 0.3× sequencing coverage depth per
nucleotide. Barcode Indexing was used in both PGM and
Proton chips. The index served as a token to differentiate
each sample from the multiplexed sample mixtures.
Table 1 Demographic characteristics. Demographic characteristics of 101 pregnant women in Mirae & Heemang, Namujungwon,
and GN hospitals in Korea
Demographic characteristics Euploid (n = 96) T21 (n = 5) P value Total (n = 101)
Maternal age, years, mean ± SD 35.55 ± 3.63 33.40 ± 3.64 35.45 ± 3.64
≥35 years (%) 59 (61.46) 1(20.00) 60 (59.41)
NIPT during gestational week 11–13 (%) 67 (69.79) 3 (60.0) 70 (69.31)
NIPT during gestational week 14–18 (%) 29 (30.21) 2 (40.0) 31 (30.69)
PGM, z-score of chr21 (min, max) −3.46, 2.07 5.50, 9.43 <0.0001† −3.46, 9.43
Proton, z-score of chr21 (min, max) −2.32, 2.10 6.20, 8.86 <0.0001† −2.32, 8.96
T21 Trisomy 21, SD standard deviation, NIPT non-invasive prenatal testing. P values from †Student’s t-test
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Data analysis
DNA fragments with different lengths derived from the
Ion Torrent Suite software were trimmed from the 3'
end using a sequencing quality value of >15 and filtered
by read length (<50 bp) and GC contents (35–45 %).
The Picard program (http://broadinstitute.github.io/pic-
ard/) was used to remove duplicate DNA reads. The se-
quence fragments from each sample were then mapped
to the human reference genome sequence (hg19). We
evaluated BWA [28], Bowtie [29], and SOAP2 [30] map-
ping software and chose BWA to acquire the final map-
ping results. Every chromosome was divided into
segments with a bin size of 300 kb to calculate the z-
scores to determine trisomy 21. For all 101 samples, we
calculated the z-score for each chromosome of each
sample to detect the aneuploidy with mapped reads, as
well as the average mapped reads and standard deviation
(SD) of 96 euploid samples. The z-score of case 1 for
chr21, for example, was calculated as follows: z-
scorechr21_case1 = (mapped reads of chr21case1 – mean
mapped reads of chr21euploid group)/(SD for mean
mapped reads of chr21euploid group). The minimal z-
scores to determine negative versus positive cases of tri-
somy were > 2.07 and > 2.10 for fetal trisomy 21 for
PGM and Proton systems, respectively. We used Stu-
dent’s t-test to evaluate the statistical significance of the
comparison between the euploid and T21 groups, and a
value < 0.05 was considered statistically significant.
Results
By comparing the sequencing results, we found that the
sequencing qualities of both platforms were slightly dif-
ferent, although they are very similar sequencers from
the same company. The average total reads of the 101
samples were approximately 4.5 and 7.6 M for PGM and
Proton, respectively. For the 318 chip of the PGM se-
quencer, the average read mapped ratio was higher with
a lower SD, the mean read length was longer with a
higher SD and the Phred quality score was higher with a
higher SD. The Proton PI chip had a better correlation
coefficient between the chromosome length and the total
reads of the corresponding chromosome. However, we
observed that the sequencing quality differences between
both platforms did not affect the final z-score results, indi-
cating that the number of DNA reads is more important
than individual sequence fragment quality. Interactive dot
diagrams for fetal trisomy 21 for the PGM and Proton sys-
tems showed the smallest z-score values of 100 % positive
predictive value (PPV) and negative predictive value
(NPV) (Fig. 1). Figure 2 shows a comparison for an identi-
cal sample sequenced by PGM and Proton platforms. The
z-scores of the negative samples showed almost the same
trends between the platforms, while those of the positive
samples showed the same trends. For PGM, the smallest
z-score value of 2.07 showed a 100 % PPV and NPV. The
minimal z-score of 2.10 was used to classify negative ver-
sus positive cases for the Proton system. Table 2 shows
the PPVs and NPVs of the NIPT outcomes for fetal tri-
somy 21 for PGM and Proton, respectively. For both
PGM and Proton, the PPV (95 % CI: 47.8–100.0 %) and
NPV (95 % CI: 96.2–100.0 %) were 100 %.
Discussion
We compared the PGM with Proton ion semiconductor
systems by performing NIPT using cfDNA in a high-risk
population. Comparison of the PGM 318 and Proton PI
chips was performed with five different parameters
to measure their sequencing quality, which revealed
sequencer-specific differences (Table 3). However, the
two different platforms showed the same accuracy
(100 %) using the same set of samples. Our results
suggested that prenatal prediction of Down syndrome
could be performed equally well by both semiconductor-
based sequencing platforms. In addition, we found that
early fetal aneuploidy detection (weeks 11–13 of preg-
nancy) is possible, in addition to detection in the late stage
of pregnancy.
Previous studies detected no quality differences between
Ion Torrent sequencer and the nucleotide synthesis-
based Illumina sequencers by comparing PGM data
vs. HiSeq2000- and MiSeq-derived data, although the
error rate of PGM data was relatively higher than
Fig. 1 Dot diagrams. Interactive dot diagrams of trisomy 21 for PGM and Proton sequencers showing the minimal z-scores
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those of the HiSeq2000 and MiSeq data [31, 32].
Chen et al. [33] evaluated the performances of Proton
and MiSeq systems for extremely low-coverage se-
quencing, and showed that both sequencers detected
aneuploidies correctly. Wang et al. concluded that the
data quality of Ion Torrent PGM was generally better
than that of the Proton system [26]. However, they
showed that both PGM- and Proton-based semicon-
ductor high-throughput sequencing was feasible in
the noninvasive prenatal testing of fetal aneuploidies
[26], although it was carried out with a very small
number of samples. In our previous study, we showed
that the detection of fetal T18 and T21 could be car-
ried out using the Ion Torrent Proton system [10]. A
large-scale clinical study by Liao et al. also showed
that NIPT using an Ion Proton sequencer could be
successful [23]. In addition, the Ion Proton system can
generate about 80 million raw reads in 3–4 h, allowing
chromosomal aneuploidy detection in 2 working days.
Hence, it could be suitable for operations that require fast
and accurate turnaround times [33].
Conventional prenatal screening is not perfect and its
detection accuracy for chromosomal aneuploidy is below
100 %. Screens using maternal serum markers and ultra-
sound have been approved, but have lower accuracy.
Henry et al. [34] analyzed Down syndrome births after
routine noninvasive screening, based on conventional,
non-sequencing tests, which have mostly replaced age-
related invasive processes. They found that despite the
increase in prenatal screening, newborn children with
Down syndrome increased in women over the age of
35 years, because the mothers believed that a single
blood test would be sufficient to detect trisomy 21.
A positive NIPT result should include a follow-up test
with an invasive prenatal method to confirm the fetal
chromosomal aneuploidies. Accurate detection of com-
mon chromosomal aneuploidies, particularly T18 and
T21, has been consistently reported in previous works of
NIPT using cfDNA [18–23]. The current price of a
plasma cfDNA test is $800–2000 in the US and $500–
1500 in some other countries [8]. Two previous studies
evaluated the cost of a cfDNA test in women with posi-
tive prevalent screening outcomes and concluded that
the use of the cfDNA test was associated with a net
price reduction compared with conventional CVS or
amniocentesis [35, 36]. One limitation of our current
study is that it could not detect additional positive cases
for other common chromosomal aneuploidies, such as
T18 and T13.
In terms of the time to perform NIPT, a previous
study [10] reported that for high sensitivity and spe-
cificity, the samples should be collected during weeks
14–21 of gestation. It is advantageous to find a chro-
mosomal abnormality at an early stage of pregnancy;
therefore, it is crucial to investigate whether a similar ac-
curacy could be achieved in early pregnancy to expand
the clinical utility of NIPT. Our current results indicated
that both semiconductor-based platforms are sufficiently
sensitive and effective for pregnant women, most of
which were at 11 to 13 weeks of gestation.
Although both the PGM and Proton platforms yielded
similar results for NIPT, using the minimal z-scores
Fig. 2 Z-score comparison between PGM and Proton platforms using identical samples
Table 2 Positive and negative predictive values. The positive and negative predictive values of the NIPT results for fetal trisomy 21
for the PGM and Proton sequencers used in this study
Chip Positive predictive value (95 % CI) Negative predictive value (95 % CI)
318 of PGM 100.0 % (47.8–100.0 %) 100.0 % (96.2–100.0 %)
PI of Proton 100.0 % (47.8–100.0 %) 100.0 % (96.2–100.0 %)
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thresholds identified here for classification cannot be a
standard measure, because there is usually a grey zone
where the classification is not certain and further inves-
tigation is required. Therefore, a larger sample size is
required to confirm the reliability and validity of our
results.
Conclusions
We showed that fetal trisomy 21 could be detected suc-
cessfully by two different ion semiconductor sequencers
(Ion Torrent PGM and Proton) and confirmed that both
Ion chips are suitable for cfDNA screening for pregnant
women at an early stage. In Korea, PGM is approved as
a medical instrument for cfDNA testing, while the Proton
awaits approval. Therefore, our investigation provided
evidence of PGM’s applicability to public clinical tests. As
PGM has been used for NIPT for some years, these results
could be used in other countries where NIPT is provided
to pregnant women.
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